Search J Rheum

Advanced Search

Home

Current Issue

Archives

Guidelines for Authors & Reviewers

Classified Ads

Links

Search PubMed

Subscriptions

Subscriber Registration

Guidelines for Website Users

JRheum Update Service

Contact Info


Download PDF


View Table of Contents

Diagnostic and Prognostic Significance of Measuring Antibodies to a-Fodrin Compared to Anti-Ro-52, Anti-Ro-60, and Anti-La in Primary Sjögren's Syndrome

HENNING LOCHT, RANDI PELCK, and ROLF MANTHORPE

ABSTRACT.

Objective.
To compare sensitivity and specificity of autoantibodies to a-fodrin with conventional anti-Ro and anti-La antibodies in patients with primary Sjögren's syndrome (pSS). Data on internal organ manifestations were correlated with presence of autoantibodies.

Methods. We collected clinical and laboratory data from 321 patients with pSS (Copenhagen criteria), of which 205 fulfilled the new American-European 2002 consensus criteria. Sera were tested for autoantibodies against a-fodrin and recombinant Ro-52, Ro-60, and La proteins.

Results. Antibodies to a-fodrin were not diagnostically superior to conventional anti-Ro/La testing. IgG anti-La had the highest specificity (97%). A highly significant association was found between presence of anti-La and internal organ manifestations (OR 6, 95% CI 2.99-12.03) or hematological abnormalities. The pattern of autoantibodies was relatively independent of disease duration, indicating that these antibodies appeared early in pSS, probably even years before the first symptoms were manifest.

Conclusion. We could not confirm that antibodies to a-fodrin had higher specificity or sensitivity than anti-Ro/La. Anti-La antibodies were strongly correlated to organ involvement and cytopenias, and thus could serve as a prognostic marker in pSS. (J Rheumatol First Release Mar 15 2008)

Key Indexing Terms:

PRIMARY SJÖGREN'S SYNDROME
ANTI-RO-52
ANTI-RO-60
ANTI-LA
ANTI-a-FODRIN


From the Department of Autoimmunology, Statens Serum Institut, Copenhagen, Denmark; and the Sjögren's Syndrome Research Centre, Malmö, Sweden.

H. Locht, MD; R. Pelck, MD, Department of Autoimmunology, Statens Serum Institut; R. Manthorpe, MD, Sjögren's Syndrome Research Centre.

Address reprint requests to Dr. H. Locht, Department of Autoimmunology, Bldg 81/5, Artillerivej 5, Statens Serum Institut, DK-2300 Copenhagen S, Denmark. E-mail: hlo@ssi.dk

Accepted for publication December 3, 2007.



Return to First Release Table of Contents



© The Journal of Rheumatology Publishing Company Limited.
All rights reserved.